metastatic-lung-cancer-therapy.com - Treatment for Certain Types of EGFR+ NSCLC | TAGRISSO® (osimertinib)

home > domains > metastatic-lung-cancer-therapy.com

Description: Learn about TAGRISSO® (osimertinib), a targeted treatment option for people with certain types of EGFR+ non-small cell lung cancer (NSCLC). Talk to your doctor to see if TAGRISSO is right for you.

Example domain paragraphs

CHOOSE YOUR INDICATION

What is TAGRISSO approved to treat?

For people with early-stage (stage 1-3) EGFR+ NSCLC after surgery,